ABOUT US

MULTIPLEX AI

MultiplexAI delivers fast, accurate, and affordable parasite diagnosis at the point of care — saving lives and strengthening health systems.

We bring expert-level diagnostics to every clinic, everywhere, using AI to turn ordinary microscopes into powerful tools for global health.

Remote clinics need fast, reliable tools that fit their reality.

THE CHALLENGE

Microscopy saves lives,
but it comes with flaws

Parasitic diseases like malaria and neglected tropical diseases (NTDs) affect hundreds of millions, yet diagnosis still relies on traditional microscopy.

This method is labour-intensive, varies with the skill of the analyst, and misdiagnosis rates can exceed 50%. Delayed or incorrect diagnoses fuel transmission, worsen outcomes, and strain fragile health systems.

THE SOLUTION

Turning any microscope
into a smart AI assistant.

MultiplexAI upgrades a standard optical microscope into a low-cost, mobile-powered diagnostic system. Using advanced AI, it performs comprehensive sample analysis, by detecting, differentiating, and quantifying multiple parasites in minutes at the point of care.

Designed for real-world use, it is scalable, works offline, and is guided by WHO’s principles of trustworthy AI.

AI FOR MICROSCOPY

MultiplexAI integrates a smartphone app, AI models, and 3D-printed microscope adaptors to deliver expert-level results in real time, even without internet connectivity.

IMPACT

Accurate diagnosis, everywhere.

MultiplexAI will expand access to expert-level diagnostics in resource-limited settings, helping healthcare workers deliver timely treatment and reduce transmission. By strengthening disease surveillance, supporting health systems, and cutting costs linked to misdiagnosis, the project advances universal health coverage and contributes to global goals for equity and well-being.

Clinical
Excellence

  • Automates parasite detection with ≥95% accuracy
  • Accelerates diagnosis and treatment at the point of care
  • Reduces misdiagnosis and variability across users

Equity &
Accessibility

  • Works offline on standard smartphones
  • Adaptable to different skill levels and health systems
  • Designed for remote and underserved regions

Economic &
Capacity Impact

  • Saves health system costs by reducing delays and hospitalizations
  • Builds local skills through training and digital literacy
  • Creates scalable pathways to regulatory approval and market entry

Sustainability &
Long-Term Value

  • Energy-efficient, upgradable system with minimal environmental footprint
  • Supports broader applications beyond parasitic diagnosis
  • Contributes to global health equity and digital public goods

AI-generated image

HOW WE DO IT?

MultiplexAI harnesses artificial intelligence and mobile technology to transform microscopy into an accessible, expert-level diagnostic tool, delivering accurate, affordable, and universal health diagnostics for everyone, everywhere

GLOBAL OBJECTIVE

The overall objective is to enhance the local diagnostic capabilities at the POC for malaria and NTDs through an interactive AI copilot leveraging computer vision and automatic mobile microscopy.

SPECIFIC GOALS

  • To design a trustworthy diagnostic AI system, ensuring technical robustness and adherence to the WHO AI ethical principles of safety, transparency, explainability, accountability, equity, and sustainability.
  • To develop AI models for microscopy analysis capable of automating the detection, differentiation and quantification of blood cells and multiple parasites, and integrate them into an automatic mobile microscopy system.
  • To evaluate the performance of MultiplexAI in laboratory settings.
  • To undertake a performance evaluation study in clinical workflows of four countries in Sub-Saharan Africa (SSA).
  • To assess usability, acceptability and feasibility with end-users of different levels of training and assess the cost-effectiveness of its implementation.
  • To model the health impact of introducing our system to improve diagnosis and surveillance of parasitic diseases at both local and national level.
  • To determine a path to market access and the regulatory roadmap for compliance in EU and SSA.

TIMELINE AT A GLANCE

2025

System refinement, lab validation, and stakeholder engagement.

2026-2027

Clinical performance evaluation in SSA (Nigeria, Mozambique, Ethiopia, and Côte d’Ivoire) and Europe (Spain, Italy).

2028

Final product validation, regulatory clearance, and market launch.

TO COLLABORATE OR COVER THIS INITIATIVE, CONTACT US